KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Free Cash Flow (2016 - 2025)

Boston Scientific's Free Cash Flow history spans 17 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 14.08% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $3.7 billion, up 38.3%, while the annual FY2025 figure was $3.7 billion, 38.3% up from the prior year.
  • Free Cash Flow for Q4 2025 was $1.0 billion at Boston Scientific, down from $1.2 billion in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.2 billion in Q4 2024 and bottomed at -$179.0 million in Q1 2022.
  • The 5-year median for Free Cash Flow is $511.5 million (2023), against an average of $517.4 million.
  • The largest annual shift saw Free Cash Flow crashed 185.65% in 2022 before it skyrocketed 2460.0% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $212.0 million in 2021, then skyrocketed by 180.66% to $595.0 million in 2022, then increased by 15.97% to $690.0 million in 2023, then soared by 70.87% to $1.2 billion in 2024, then dropped by 14.08% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Free Cash Flow are $1.0 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).